Conference Call with Anupam Rasayan India Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Agrochemicals company Anupam Rasayan announced Q4FY23 & FY23 results: Q4FY23: Operating Revenues at Rs 4,800 million in Q4FY23 as compared to Rs 3,249 million in Q4FY22 – growth of 48% YoY Total Revenues at Rs 5,042 million in Q4FY23 as compared to Rs 3,169 million in Q4FY22 – growth of 59% YoY EBITDA (incl. other revenue) at Rs 1,416 million in Q4FY23 as compared to Rs 969 million in Q4FY22 – growth of 46% YoY Profit After Tax at Rs 726 million in Q4FY23 as compared to Rs 461 million in Q4FY22 - growth of 58% YoY FY23: Operating Revenues at Rs 16,019 million in FY23 as compared to Rs 10,738 million in FY22 – growth of 49% YoY Total Revenues at Rs 16,105 million in FY23 as compared to Rs 10,811 million in FY22 – growth of 49% YoY EBITDA (incl. other revenue) at Rs 4,399 million in FY23 as compared to Rs 3,121 million in FY22 – growth of 41% YoY Profit After Tax at Rs 2,168 million in FY23 as compared to Rs 1,522 million in FY22 - growth of 42% YoY Speaking on the performance, Anand Desai, Managing Director, Anupan Rasayan commented, "It gives me pleasure to share that we have continued our growth momentum with a 49% YoY revenue growth on the back of new products commercialized during the year as well as steady growth of the organic portfolio. On the operations part, we continue to focus on adding more value-added products in our basket as well as bringing financial efficiencies. We have already started witnessing the results of the same which is visible in stable margins and improved working capital resulting in strong cash generation of Rs 2,440 million from operations. Our strategic investments in infrastructure, people and technology have also started yielding great results which is visible in the growth that we have delivered as well as the new LOIs we have signed where majority of the customers are new clients. We will not stop here and further invest in strengthening and expanding these pillars of growth. As we stand, we have signed contracts and LOIs of Rs 54,830 million giving us a strong revenue visibility for the coming years. At the same time, we are witnessing a robust traction in customer engagement as we remain in advance stage of discussions with customers across geographies for many niche and high value molecules. All these factors give us a reassurance of sustained robust growth in FY24.” Result PDF
Conference Call with Anupam Rasayan India Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.